Integrated approach to personalized cancer diagnosis and therapy /
Endocrinology

Research program on pituitary, adrenal and thyroid tumorigenesis and mechanisms of drug resistance
The lines of research the laboratory is involved in are focused on:

• pituitary tumors;
• adrenal tumors;
• medullary thyroid carcinoma.

In particular, our laboratory is concerned with investigating the molecular mechanisms underlying cancer cell growth and those implicated in drug resistance, with the aim of identifying possible new therapeutic targets and new biomarkers that can predict response to currently used drug treatments

Research program on endocrinological disorders
The team participates in numerous clinical trials on pituitary tumors, Cushing's syndrome and disease, acromegaly, growth hormone deficiency (GHD) in adults in transition age and children, pituitary dwarfism, pituitary uni- and pluritropinic secretory deficits, panhypopituitarism, syndrome of inappropriate antidiuretic hormone secretion, diabetes, thyroid and adrenal pathologies, osteoporosis, rare diseases, and genetic diseases of the endocrine-metabolic system.
Innovative drug trials (Phases Ib- IV) particularly in the following diseases: diabetes mellitus type 1 and 2, endocrine ophthalmopathy, acromegaly, Cushing's syndrome, GH deficiency in children and adults, hypoparathyroidism, autosomal dominant hypocalcemia (ADH), advanced thyroid medullary K, osteoporosis, and rare bone diseases.
Observational studies on epidemiology, diagnosis, complications and treatment in different areas of endocrinology such as: acromegaly, Cushing's syndrome, non-functioning adenomas, Rathke's cysts, empty sella and other antero-pituitary disorders, GH deficiency particularly neonatal, diabetes insipidus, SIAD, male hypogonadism, precocious puberty, pubertal induction in girls, MEN, thyroid cancers with special interest in medullary one, thyroid complications of drug therapies and viral infections including COVID-19, endocrine ophthalmopathy, adrenal tumors, pheochromocytomas and paragangliomas, hypo- and hyperparathyroidisms, pseudohypoparathyroidisms, androgen insensitivity syndrome, osteoporosis, and rare bone diseases.